Comorbidity of allergic rhinitis and bronchial asthma: principles of diagnostics and therapy

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

High prevalence of the combination of allergic bronchial asthma (BA) and allergic rhinitis (AR) allows us to consider the latter to be an independent risk factor for the development of BA. In patients with comorbid BA and AR with uncontrolled AR, the frequency of asthma attacks, emergency care applications, unscheduled visits to the doctor, hospitalizations, and the need for systemic glucocorticosteroids are increasing. Uncontrolled clinical course of BA in this category of patients is observed 4–5 times more often than in patients without concomitant AR. Intranasal glucocorticosteroids are the first-line drugs in patients with moderate to severe course of AR, especially with severe nasal obstruction. Mometasone furoate is one of the most studied drugs in that class. High efficacy and safety of mometasone furoate, proven in a large number of studies, including in patients with a combination of AR and bronchial asthma, justify its choice for basic therapy of AR in comorbid patients.

全文:

受限制的访问

作者简介

Laura Bolieva

North Ossetian State Medical Academy of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: bolievalz@mail.ru
ORCID iD: 0000-0002-1820-7726
SPIN 代码: 1811-9351

MD, Dr. Sci. (Medicine), professor, head of the Department of pharmacology with clinical pharmacology

俄罗斯联邦, Vladikavkaz

参考

  1. Клинические рекомендации. Аллергический ринит. Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, Национальная медицинская ассоциация оториноларингологов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 261_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/261_2 (дата обращения – 21.05.2025). [Clinical guidelines. Allergic rhinitis. Russian Association of Allergologists and Clinical Immunologists, National Medical Association of Otorhinolaryngologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 261_2. URL. https://cr.minzdrav.gov.ru/preview-cr/261_2 (date of access – 21.05.2025) (In Russ.)].
  2. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–58. PMID: 28602936. http://doi.org/10/1016/j/jaci.2017.03.050
  3. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al.; World Health Organization; GA(2)LEN; AllerGen. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. PMID: 18331513. http://doi.org/10.1111/j.1398-9995.2007.01620.x
  4. Хаитов М.Р., Намазова-Баранова Л.С., Ильина Н.И., Курбачева О.М., Bachert C., Hellings P.W. с соавт. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский аллергологический журнал. 2020;17(1):7–22. [Khaitov MR, Namazova-Baranova LS, Ilyina NI, Kurbacheva OM, Bachert C, Hellings PW et al. 2019 ARIA: Care pathways for allergic rhinitis in Russia. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2020;17(1):7–22 (In Russ.)]. EDN: HHBTEI. http://doi.org/10.36691/RAJ.2020.17.1.001
  5. Wise SK, Lin SY, Toskala E, Orlandi R, Akdis CA, Alt JA et al. International consensus statement on allergy and rhinology: Allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. https://doi.org/10.1002/alr.22073
  6. Бондарева Г.П., Вылегжанина Т.Г., Данилычева И.В., Елисютина О.Г., Емельянов А.В., Костинов М.П. с соавт. Аллергология и иммунология: национальное руководство. Под ред. Хаитова Р.М., Ильиной Н.И. М.: ГЭОТАР-Медиа. 2009; 656 с. [Bondareva GP, Vylegzhanina TG, Danilycheva IV, Elisyutina OG, Emelyanov AV, Kostinov MP et al. Allergology and immunology: National guidelines. Edited by Khaitov R.M., Ilina N.I. Moscow: GEOTAR-Media. 2009; 656 pp. (In Russ.)]. ISBN: 978-5-9704-0903-9. EDN: TCKPSZ.
  7. Астафьева Н.Г., Баранов А.А., Вишнева Е.А., Дайхес Н.А., Жестков А.В., Ильина Н.И. с соавт. Аллергический ринит. Российский аллергологический журнал. 2022;19(1):100–141. [Astafieva NG, Baranov AA, Vishneva EA, Daikhes NA, Zhestkov AV, Ilina NI et al. Allergic rhinitis. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2022;19(1):100–141 (In Russ.)]. EDN: WGQIPE. http://doi.org/10.36691/RJA1524
  8. Хаитов М.Р., Намазова-Баранова Л.С., Чучалин А.Г., Дайхес Н.А., Ильина Н.И., Курбачева О.М. с соавт. ARIA 2016: Современные направления оказания медицинской помощи больным аллергическим ринитом в свете требований прецизионной медицины. Российский аллергологический журнал. 2017;14(3):46–54. [Khaitov MR, Namazova-Baranova LS, Chuchalin AG, Daikhes NA, Ilina NI, Kurbacheva OM et al. ARIA 2016: Integrated care pathways for predictive medicine across the life cycle. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2017;14(3):46–54 (In Russ.)]. EDN: ZFUACR.
  9. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998;101(2 Pt 2):S352–56. PMID: 9500726. http://doi.org/10.1016/s0091-6749(98)70218-0
  10. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: Data from the second National Health and Nutrition Examination Survey, 1976–80 (NHANES II). J Allergy Clin Immunol. 1992;90(4 Pt 1):579–88. PMID: 1401641. http://doi.org/10.1016/0091-6749(92)90130-t
  11. Greisner WA 3rd, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: A 23-year follow-up study of college students. Allergy Asthma Proc. 1998;19(4):185–88. PMID: 9727149. http://doi.org/10.2500/108854198778557836
  12. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419–25. PMID: 11897985. http://doi.org/10.1067/mai.2002.121701
  13. Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. World Allergy Organ J. 2019;12(10):100069. PMID: 31660100. PMCID: PMC6807062. http://doi.org/10.1016/j.waojou.2019.100069
  14. Vignola AM, Chanez P, Godard P, Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53(9):833–39. PMID: 9788683. http://doi.org/10.1111/j.1398-9995.1998.tb03988.x
  15. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J et al. Rhinitis and onset of asthma: A longitudinal population-based study. Lancet. 2008;372(9643):1049–57. PMID: 18805333. http://doi.org/10.1016/S0140-6736(08)61446-4
  16. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт. 1998; 252 с. [Gushchin IS. Allergic inflammation and its pharmacological control. Moscow: Farmarus Print. 1998; 252 pp. (In Russ.)]. ISBN: 5-901029-04-6.
  17. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836–44. PMID: 15256389. http://doi.org/10.1164/rccm.200401-033OC
  18. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: Results of a 2008 survey. Eur Respir Rev. 2010;19(116):150–57. PMID: 20956184. PMCID: PMC9682581. http://doi.org/10.1183/09059180.00002110
  19. Архипов В.В., Прозорова В.К. Контроль над астмой: проблемные аспекты. Consilium Medicum. 2012;14(11):47–51. [Arkhipov VV, Prozorova VK. Asthma control: Problematic aspects. Consilium Medicum. 2012;14(11):47–51 (In Russ.)]. EDN: RAIFRR.
  20. Bousquet J, Gaugris S, Sazonov Kocevar V, Zhang Q, Yin DD, Polos PG, Bjermer L. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: A subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy. Clin Exp Allergy. 2005;35(6):723–27. PMID: 15969661. http://doi.org/10.1111/j.1365-2222.2005.02251.x
  21. Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009;18(4):300–5. PMID: 19562233. PMCID: PMC6619365. http://doi.org/10.4104/pcrj.2009.00037
  22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23. PMID: 16236742. http://doi.org/10.1056/NEJMra050541
  23. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: A non-genomic anti-inflammatory switch. Eur J Pharmacol. 2008;583(2–3):322–39. PMID: 18295199. PMCID: PMC2367369. http://doi.org/10.1016/j.ejphar.2007.12.033
  24. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: A meta-analysis. Allergy. 2013;68(5):569–79. http://doi.org/10.1111/all.12124
  25. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: Clinical and therapeutic implications. Allergy. 2008;63(10):1292–1300. PMID: 18782107. https://doi.org/10.1111/j.1398-9995.2008.01750.x
  26. Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54. PMID: 17650349. PMCID: PMC1950704. https://doi.org/10.1186/1465-9921-8-54
  27. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? J Allergy Clin Immunol. 1999;104(4 Pt 1):S144–49. PMID: 10518811. https://doi.org/10.1016/s0091-6749(99)70310-6
  28. Samolinski B, Nowicka A, Wojas O, Lipiec A, Krzych-Fałta E, Tomaszewska A. Intranasal glucocorticosteroids – not only in allergic rhinitis in the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014;68(2):51–64. PMID: 24629736. https://doi.org/10.1016/j.otpol.2013.12.003
  29. Sharpe SA, Sandweiss V, Tuazon J, Giordano M, Witchey-Lakshmanan L, Hart J, Sequeira J. Comparison of the flow properties of queous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003;29(9):1005–12. PMID: 14606664. https://doi.org/10.1081/ddc-120025457
  30. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН мометазон в лекарственной форме спрей назальный / спрей назальный дозированный. Доступ: https://grls.minzdrav.gov.ru/GRLS.aspx?RegNumber=&MnnR=мометазон&lf=спрей+назальный&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&token=6a83e2c8-cda6-47dc-b12d-972871b0043b&order=Registered&orderType=desc&pageNum=1 (дата обращения – 21.07.2025). [State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drugs with INN mometasone n the dosage form of nasal spray / dosed nasal spray. URL: https://grls.minzdrav.gov.ru/GRLS.aspx?RegNumber=&MnnR=мометазон&lf=спрей+назальный&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&token=6a83e2c8-cda6-47dc-b12d-972871b0043b&order=Registered&orderType=desc&pageNum=1 (date of access – 21.07.2025) (In Russ.)].
  31. Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: A systematic review. Multidiscip Respir Med. 2016;11:18. PMID: 27141307. PMCID: PMC4852427. http://dx.doi.org/10.1186/s40248-016-0054-3
  32. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol. 1998;102(1):39–49. PMID: 9679846. https://doi.org/10.1016/s0091-6749(98)70053-3
  33. Berkowitz RB, Roberson S, Zora J, Capano D, Chen R, Lutz C, Harris AG. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 1999;20(3):167–72. PMID: 10389549. https://doi.org/10.2500/108854199778553037
  34. Clement P, Gates D. Symptom suppression in subjects with perennial allergic rhinitis treated with mometasone furoate nasal spray. Int Arch Allergy Immunol. 2012;157(4):387–90. PMID: 22123158. https://doi.org/10.1159/000329524
  35. Meltzer EO, Blaiss MS, Naclerio RM, Stoloff SW, Derebery MJ, Nelson HS et al. Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(1 Suppl):S113–41. PMID: 22981425. https://doi.org/10.2500/aap.2012.33.3603
  36. Popov TA, Kralimarkova TZ, Staevska MT, Dimitrov VD. Characteristics of a patient population seeking medical advice for nasal symptoms in Bulgaria. Ann Allergy Asthma Immunol. 2012;108(4):232–36. PMID: 22469441. https://doi.org/10.1016/j.anai.2012.02.009
  37. Thompson A, Sardana N, Craig TJ. Sleep impairment and daytime sleepiness in patients with allergic rhinitis: The role of congestion and inflammation. Ann Allergy Asthma Immunol. 2013;111(6):446–51. PMID: 24267356. https://doi.org/10.1016/j.anai.2013.05.020
  38. Salapatek AM, Patel P, Gopalan G, Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010;24(6):433–38. PMID: 21067660. https://doi.org/10.2500/ajra.2010.24.3548
  39. Urdaneta E, Tunceli K, Gates D. Effect of mometasone furoate nasal spray on moderate-to-severe nasal congestion in seasonal allergic rhinitis: A responder analysis. Allergy Asthma Proc. 2019;40(3):173–79. PMID: 31018892. https://doi.org/10.2500/aap.2019.40.4214
  40. Baiardini I, Villa E, Rogkakou A, Pellegrini S, Bacic M, Compalati E et al. Effects of mometasone furoate on the quality of life: A randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy. 2011;41(3):417–23. PMID: 21121983. https://doi.org/10.1111/j.1365-2222.2010.03660.x
  41. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29(6):403–13. PMID: 19144302. PMCID: PMC7115254. http://dx.doi.org/10.1016/j.amjoto.2007.11.004
  42. Daley-Yates PT, Larenas-Linnemann D, Bhargave C, Verma M. Intranasal corticosteroids: Topical potency, systemic activity and therapeutic index. J Asthma Allergy. 2021;14:1093–1104. PMID: 34526783. PMCID: PMC8436259. http://dx.doi.org/10.2147/JAA.S321332
  43. Schafer T, Schnoor M, Wagenmann M, Klimek L, Bachert C. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011;49(3):272–80. PMID: 21858255. https://doi.org/10.4193/Rhino10.170
  44. Lee DK, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br J Clin Pharmacol. 2003;55(3):310–13. PMID: 12630983 PMCID: PMC1884214. https://doi.org/10.1046/j.1365-2125.2003.01729.x
  45. Minshall E, Ghaffar O, Cameron L, O’Brien F, Quinn H, Rowe-Jones J et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998;118(5):648–54. PMID: 9591864. https://doi.org/10.1177/019459989811800514
  46. Wu EL, Harris WC, Babcock CM, Alexander BH, Riley CA, McCoul ED. Epistaxis risk associated with intranasal corticosteroid sprays: A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(1):18–27. PMID: 30779679. https://doi.org/10.1177/0194599819832277

补充文件

附件文件
动作
1. JATS XML
下载
2. 1. The incidence of bronchial asthma in patients with allergic rhinitis, non-allergic rhinitis, atopy without rhinitis, and in healthy individuals [15]

下载 (69KB)
索引源数据
3. 2. Indicators of bronchial asthma control in patients with and without concomitant allergic rhinitis [20]

下载 (83KB)
索引源数据

版权所有 © Bionika Media, 2025